Key Stats for HCA Healthcare Stock
- Past-Week Performance: -3.5%
- 52-Week Range: $307.4 to $552.9
- Current Price: $259.7
What Happened?
HCA Healthcare (HCA) delivered its 19th consecutive quarter of volume growth, generating $12.6 billion in operating cash flow while the stock at $529.7 sits just 4.2% below its 52-week high of $552.9.
Driving the momentum, Bernstein raised its HCA price target to $541 from $503 on February 9, signaling growing institutional conviction in HCA’s ability to absorb ACA headwinds without margin deterioration.
Powering the thesis, HCA grew adjusted EBITDA 12.1% in 2025 while diluted adjusted EPS surged 28.5%, with the Board authorizing a fresh $10 billion share repurchase program alongside a dividend increase to $0.78 quarterly.
Beyond the current results, the market is actively re-rating HCA from a cyclical hospital operator into a durable, AI-powered healthcare compounder with a $400 million resiliency program absorbing policy headwinds.
CEO Samuel N. Hazen stated on the Q4 earnings call that “our networks had approximately 47 million patient encounters during the year, representing a record level of patient care activity,” contextualizing 19 consecutive quarters of volume growth.
Further reinforcing conviction, HCA scheduled presentations at six major investor conferences in March, including TD Cowen on March 3 and Barclays Global Healthcare on March 10, signaling management’s confidence in the 2026 outlook.
Looking ahead, HCA’s $5.0 to $5.5 billion capital plan, 2,700-plus outpatient facilities, and AI clinical agenda position it to dominate U.S. hospital market share well through the end of the decade.
Wall Street’s Take on HCA Stock
HCA’s $10 billion share repurchase authorization and six March investor conference appearances directly signal management’s confidence in absorbing the $600 million to $900 million ACA headwind without breaking earnings momentum.
Fundamentally, HCA grew normalized EPS 28.5% to $28.2 in 2025 while EBITDA expanded 12.1% to $15.6 billion, with 2026 consensus forecasting further EPS growth to $30.3.
Currently, 13 analysts rate HCA a Buy and 2 rate it Outperform, with a mean price target of $541.5, implying 2.2% upside from $529.7, suggesting analysts are upgrading into existing strength.
Notably, the target range spans $425.0 to $635.0, where the high end requires successful ACA headwind absorption and resiliency execution, and the low end prices in full EBITDA deterioration from exchange volume losses.
What Does the Valuation Model Say?
TIKR’s mid-case model targets $840.9 by December 2030, delivering a 58.7% total return at a 10.0% IRR from today’s $529.7.
The model signals HCA trades at a meaningful discount despite generating $12.6 billion in operating cash flow in 2025.
The market prices HCA as an ACA-exposed hospital operator, yet the $400 million resiliency program directly offsets the exchange headwind.
HCA’s 19 consecutive quarters of volume growth confirm this is a structural compounder, not a policy-dependent business.
CEO Samuel N. Hazen’s statement that 47 million patient encounters represented “a record level of patient care activity” signals demand is structural, not cyclical.
However, if the ACA exchange volume decline exceeds 20% and the $400 million resiliency program falls short, the $15.55 billion EBITDA floor collapses immediately.
Watch HCA’s Q1 2026 exchange volume data, the single metric that confirms whether the 15% to 20% decline assumption holds.
HCA is undervalued at $529.7 with a $840.9 model target and 10.0% IRR; watch Q1 exchange volume data closely.
Should You Invest in HCA Healthcare, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HCA stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track HCA Healthcare, Inc.alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HCA stock on TIKR for Free →
